NeuroPace Reports First Quarter 2024 Financial Results and Provides Corporate Update Revenue increased to $18.1 million in Q1 2024, a 25% increase over Q1 2023 Extended the maturity date of the Company's term loan by one year to September 30, 2026 Maintained full-year 2024 revenue guidance of $73 to $77 million Management scheduled to host a conference call today at 4:30 p.m. ET Mountain View, Calif. – May 8, 2024 – NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives o ...